[Reassessment of second-look operations (SLO) in the treatment of ovarian cancer].
To reassess the role off SLO in the ovarian cancer, 96 patients who underwent second laparotomy from 1968 to 1987 in our department were studied. 59 out of 96 (60.5%) were completed primary surgery while rest of them (39.5%) were incompletely resected. SLO was carried out in 34 patients of former group (57.6%) and in 9 patients in later group (24.3%). Recurrence was found in 3 patients of complete primary surgery + SLO (group A) whereas 5 patients of incomplete primary surgery + SLO (group C). Recurrence rate was significantly lower in group A. There was no relationship between the site of recurrence and survival time. Until we obtain a good tool to detect recurrence site, SLO has an important role for the management of patients. Combination of radical debulking surgery and CAP regimen with 70 mg/m2 of CDDP at least for 2 years with SLO is considered to be important to improve prognosis and quality of life of ovarian cancer patients.
Ochiai
K
K
Dept. of Obstetrics and Gynecology, Jikei University School of Medicine.
D000328:Adult; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002945:Cisplatin / Q000008:administration & dosage; D003131:Combined Modality Therapy; D003520:Cyclophosphamide / Q000008:administration & dosage; D004317:Doxorubicin / Q000008:administration & dosage; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000401:mortality / Q000601:surgery; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000401:mortality / Q000601:surgery*; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000556:secondary / Q000601:surgery; D011379:Prognosis; D012008:Recurrence; D012086:Reoperation
D004317:Doxorubicin; D003520:Cyclophosphamide; D002945:Cisplatin